Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2016, Article ID 8671762, 17 pages
http://dx.doi.org/10.1155/2016/8671762
Review Article

Insulin-Sensitizers, Polycystic Ovary Syndrome and Gynaecological Cancer Risk

1Unit of Endocrinology, Regina Elena National Cancer Institute, Rome, Italy
2Unit of Endocrinology, Department of Systems’ Medicine, University of Rome Tor Vergata, Section of Reproductive Endocrinology, Fatebenefratelli Hospital “San Giovanni Calibita” Rome, Italy
3Division of Medical Oncology B, Regina Elena National Cancer Institute, Rome, Italy
4Department of Gynaecologic Oncology, HPV-Unit, Regina Elena National Cancer Institute, Rome, Italy

Received 13 May 2016; Revised 12 July 2016; Accepted 8 August 2016

Academic Editor: Vittorio Unfer

Copyright © 2016 Rosa Lauretta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Asunción, R. M. Calvo, J. L. San Millán, J. Sancho, S. Avila, and H. F. Escobar-Morreale, “A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain,” The Journal of Clinical Endocrinology & Metabolism, vol. 85, no. 7, pp. 2434–2438, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. R. Azziz, K. S. Woods, R. Reyna, T. J. Key, E. S. Knochenhauer, and B. O. Yildiz, “The prevalence and features of the polycystic ovary syndrome in an unselected population,” The Journal of Clinical Endocrinology & Metabolism, vol. 89, no. 6, pp. 2745–2749, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Glintborg, “Endocrine and metabolic characteristics in polycystic ovary syndrome,” The Danish Medical Journal, vol. 63, no. 4, Article ID B5232, 2016. View at Google Scholar
  4. R. Pasquali, L. Zanotti, F. Fanelli et al., “Defining hyperandrogenism in women with polycystic ovary syndrome: a challenging perspective,” The Journal of Clinical Endocrinology & Metabolism, vol. 101, no. 5, pp. 2013–2022, 2016. View at Publisher · View at Google Scholar
  5. S. M. De Sousa and R. J. Norman, “Metabolic syndrome, diet and exercise,” Best Practice & Research Clinical Obstetrics & Gynaecology, 2016. View at Publisher · View at Google Scholar
  6. D. Heimark, J. McAllister, and J. Larner, “Decreased myo-inositol to chiro-inositol (M/C) ratios and increased M/C epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls,” Endocrine Journal, vol. 61, no. 2, pp. 111–117, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. C. N. Jayasena and S. Franks, “The management of patients with polycystic ovary syndrome,” Nature Reviews Endocrinology, vol. 10, no. 10, pp. 624–636, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. V. N. Sivalingam, J. Myers, S. Nicholas, A. H. Balen, and E. J. Crosbie, “Metformin in reproductive health, pregnancy and gynaecological cancer: established and emerging indications,” Human Reproduction Update, vol. 20, no. 6, pp. 853–868, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. A. T. Chan, “Metformin for cancer prevention: a reason for optimism,” The Lancet Oncology, vol. 17, no. 4, pp. 407–409, 2016. View at Publisher · View at Google Scholar
  10. D. R. Session, K. R. Kalli, I. S. Tummon, M. A. Damario, and D. A. Dumesic, “Treatment of atypical endometrial hyperplasia with an insulin-sensitizing agent,” Gynecological Endocrinology, vol. 17, no. 5, pp. 405–407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. R. S. Legro, R. J. Zaino, L. M. Demers et al., “The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome,” American Journal of Obstetrics and Gynecology, vol. 196, no. 4, pp. 402–410, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. Z.-Q. Shen, H.-T. Zhu, and J.-F. Lin, “Reverse of progestin-resistant atypical endometrial hyperplasia by metformin and oral contraceptives,” Obstetrics & Gynecology, vol. 112, no. 2, part 2, pp. 465–467, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. L. A. Cantrell, C. Zhou, A. Mendivil, K. M. Malloy, P. A. Gehrig, and V. L. Bae-Jump, “Metformin is a potent inhibitor of endometrial cancer cell proliferation—implications for a novel treatment strategy,” Gynecologic Oncology, vol. 116, no. 1, pp. 92–98, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. B. K. Tan, R. Adya, J. Chen, H. Lehnert, L. J. Sant Cassia, and H. S. Randeva, “Metformin treatment exerts antiinvasive and antimetastatic effects in human endometrial carcinoma cells,” The Journal of Clinical Endocrinology & Metabolism, vol. 96, no. 3, pp. 808–816, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. X. Li, Y.-R. Guo, J.-F. Lin, Y. Feng, H. Billig, and R. Shao, “Combination of diane-35 and metformin to treat early endometrial carcinoma in PCOS women with insulin resistance,” Journal of Cancer, vol. 5, no. 3, pp. 173–181, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. C. W. Ward and M. C. Lawrence, “Ligand-induced activation of the insulin receptor: a multi-step process involving structural changes in both the ligand and the receptor,” BioEssays, vol. 31, no. 4, pp. 422–434, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. The Diabetes Control and Complications Trial Research Group, “The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus,” The New England Journal of Medicine, vol. 329, no. 14, pp. 977–986, 1993. View at Publisher · View at Google Scholar
  18. J. A. Levine, K. A. Kaihara, B. T. Layden, and B. Wicksteed, “Long-term activation of PKA in beta-cells provides sustained improvement to glucose control, insulin sensitivity and body weight,” Islets, In press.
  19. D. H. Bedinger and S. H. Adams, “Metabolic, anabolic, and mitogenic insulin responses: a tissue-specific perspective for insulin receptor activators,” Molecular and Cellular Endocrinology, vol. 415, pp. 143–156, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Dupont and R. J. Scaramuzzi, “Insulin signalling and glucose transport in the ovary and ovarian function during the ovarian cycle,” Biochemical Journal, vol. 473, no. 11, pp. 1483–1501, 2016. View at Publisher · View at Google Scholar
  21. C. M. Taniguchi, B. Emanuelli, and C. R. Kahn, “Critical nodes in signalling pathways: insights into insulin action,” Nature Reviews Molecular Cell Biology, vol. 7, no. 2, pp. 85–96, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. H.-G. Joost and B. Thorens, “The extended GLUT-family of sugar/polyol transport facilitators: nomenclature, sequence characteristics, and potential function of its novel members,” Molecular Membrane Biology, vol. 18, no. 4, pp. 247–256, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. H. J. Kim, S. Y. Lee, and S. C. Oh, “The inositide signaling pathway as a target for treating gastric cancer and colorectal cancer,” Frontiers in Physiology, vol. 7, article 168, 2016. View at Publisher · View at Google Scholar
  24. J. A. Engelman, J. Luo, and L. C. Cantley, “The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism,” Nature Reviews Genetics, vol. 7, no. 8, pp. 606–619, 2006. View at Publisher · View at Google Scholar
  25. L. Xu and J. D. Ash, “The role of AMPK pathway in neuroprotection,” Advances in Experimental Medicine and Biology, vol. 854, pp. 425–430, 2016. View at Publisher · View at Google Scholar · View at Scopus
  26. F. A. Ross, T. E. Jensen, and D. G. Hardie, “Differential regulation by AMP and ADP of AMPK complexes containing different γ subunit isoforms,” Biochemical Journal, vol. 473, no. 2, pp. 189–199, 2016. View at Publisher · View at Google Scholar · View at Scopus
  27. S. A. Hawley, J. Boudeau, J. L. Reid et al., “Complexes between the LKB1 tumor suppressor, STRADα/β and MO25α/β are upstream kinases in the AMP-activated protein kinase cascade,” The Journal of Biology, vol. 2, no. 4, article 26, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. A. Woods, S. R. Johnstone, K. Dickerson et al., “LKB1 is the upstream kinase in the AMP-activated protein kinase cascade,” Current Biology, vol. 13, no. 22, pp. 2004–2008, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. K. Sakamoto, O. Göransson, D. G. Hardie, and D. R. Alessi, “Activity of LKB1 and AMPK-related kinases in skeletal muscle: effects of contraction, phenformin, and AICAR,” American Journal of Physiology—Endocrinology and Metabolism, vol. 287, no. 2, pp. E310–E317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. R. J. Shaw, M. Kosmatka, N. Bardeesy et al., “The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 10, pp. 3329–3335, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. Z. Chen, L. Wang, and Y. Chen, “Antitumor mechanism of metformin via adenosine monophosphate-activated protein kinase (AMPK) activation,” Chinese Journal of Lung Cancer, vol. 16, no. 8, pp. 427–432, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. D. G. Hardie, “AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease,” Journal of Internal Medicine, vol. 276, no. 6, pp. 543–559, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. W. Li, S. M. Saud, M. R. Young, G. Chen, and B. Hua, “Targeting AMPK for cancer prevention and treatment,” Oncotarget, vol. 6, no. 10, pp. 7365–7378, 2015. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Showkat, M. A. Beigh, and K. I. Andrabi, “mTOR signaling in protein translation regulation: implications in cancer genesis and therapeutic interventions,” Molecular Biology International, vol. 2014, Article ID 686984, 14 pages, 2014. View at Publisher · View at Google Scholar
  35. R. N. Eskander and K. S. Tewari, “Exploiting the therapeutic potential of the PI3K-AKT-mTOR pathway in enriched populations of gynecologic malignancies,” Expert Review of Clinical Pharmacology, vol. 7, no. 6, pp. 847–858, 2014. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Zoncu, A. Efeyan, and D. M. Sabatini, “mTOR: from growth signal integration to cancer, diabetes and ageing,” Nature Reviews Molecular Cell Biology, vol. 12, no. 1, pp. 21–35, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. D. R. Morales and A. D. Morris, “Metformin in cancer treatment and prevention,” The Annual Review of Medicine, vol. 66, pp. 17–29, 2015. View at Publisher · View at Google Scholar · View at Scopus
  38. K. A. Brown, N. I. Hunger, M. Docanto, and E. R. Simpson, “Metformin inhibits aromatase expression in human breast adipose stromal cells via stimulation of AMP-activated protein kinase,” Breast Cancer Research and Treatment, vol. 123, no. 2, pp. 591–596, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. K. Inoki, T. Zhu, and K.-L. Guan, “TSC2 mediates cellular energy response to control cell growth and survival,” Cell, vol. 115, no. 5, pp. 577–590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. D. M. Gwinn, D. B. Shackelford, D. F. Egan et al., “AMPK phosphorylation of raptor mediates a metabolic checkpoint,” Molecular Cell, vol. 30, no. 2, pp. 214–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. D. G. Hardie, “AMPK and Raptor: matching cell growth to energy supply,” Molecular Cell, vol. 30, no. 3, pp. 263–265, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. N. E. van der Sligte, F. J. G. Scherpen, T. G. J. Meeuwsen-de Boer et al., “Kinase activity profiling reveals active signal transduction pathways in pediatric acute lymphoblastic leukemia: a new approach for target discovery,” Proteomics, vol. 15, no. 7, pp. 1245–1254, 2015. View at Publisher · View at Google Scholar · View at Scopus
  43. B. D. Manning, A. R. Tee, M. N. Logsdon, J. Blenis, and L. C. Cantley, “Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/Akt pathway,” Molecular Cell, vol. 10, no. 1, pp. 151–162, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. C. J. Potter, L. G. Pedraza, and T. Xu, “Akt regulates growth by directly phosphorylating Tsc2,” Nature Cell Biology, vol. 4, no. 9, pp. 658–665, 2002. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Sancak, C. C. Thoreen, T. R. Peterson et al., “PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase,” Molecular Cell, vol. 25, no. 6, pp. 903–915, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Horman, D. Vertommen, R. Heath et al., “Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase α-subunits in heart via hierarchical phosphorylation of Ser485/491,” The Journal of Biological Chemistry, vol. 281, no. 9, pp. 5335–5340, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. Y. Choudhury, Z. Yang, I. Ahmad, C. Nixon, I. P. Salt, and H. Y. Leung, “AMP-activated protein kinase (AMPK) as a potential therapeutic target independent of PI3K/Akt signaling in prostate cancer,” Oncoscience, vol. 1, no. 6, pp. 446–456, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. K. Kisfalvi, G. Eibl, J. Sinnett-Smith, and E. Rozengurt, “Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth,” Cancer Research, vol. 69, no. 16, pp. 6539–6545, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Isakovic, L. Harhaji, D. Stevanovic et al., “Dual antiglioma action of metformin: cell cycle arrest and mitochondria-dependent apoptosis,” Cellular and Molecular Life Sciences, vol. 64, no. 10, pp. 1290–1302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Zakikhani, R. J. O. Dowling, N. Sonenberg, and M. N. Pollak, “The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase,” Cancer Prevention Research, vol. 1, no. 5, pp. 369–375, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. B. Markman, R. Dienstmann, and J. Tabernero, “Targeting the PI3K/Akt/mTOR pathway—beyond rapalogs,” Oncotarget, vol. 1, no. 7, pp. 530–543, 2010. View at Publisher · View at Google Scholar · View at Scopus
  52. I. A. Mayer and C. L. Arteaga, “The PI3K/AKT pathway as a target for cancer treatment,” Annual Review of Medicine, vol. 67, pp. 11–28, 2016. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Rattan, R. P. Graham, J. L. Maguire, S. Giri, and V. Shridhar, “Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo,” Neoplasia, vol. 13, no. 5, pp. 483–491, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. R. Shao, X. Li, and H. Billig, “Promising clinical practices of metformin in women with PCOS and early-stage endometrial cancer,” BBA Clinical, vol. 2, pp. 7–9, 2014. View at Publisher · View at Google Scholar · View at Scopus
  55. R. G. Jones, D. R. Plas, S. Kubek et al., “AMP-activated protein kinase induces a p53-dependent metabolic checkpoint,” Molecular Cell, vol. 18, no. 3, pp. 283–293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  56. I. Leclerc, C. Lenzner, L. Gourdon, S. Vaulont, A. Kahn, and B. Viollet, “Hepatocyte nuclear factor-4α involved in type 1 maturity-onset diabetes of the young is a novel target of AMP-activated protein kinase,” Diabetes, vol. 50, no. 7, pp. 1515–1521, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. J. Liang, S. H. Shao, Z. X. Xu et al., “The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis,” Nature Cell Biology, vol. 9, no. 2, pp. 218–224, 2007. View at Publisher · View at Google Scholar
  58. L. A. J. O'Neill and D. G. Hardie, “Metabolism of inflammation limited by AMPK and pseudo-starvation,” Nature, vol. 493, no. 7432, pp. 346–355, 2013. View at Publisher · View at Google Scholar · View at Scopus
  59. A. Gambineri, C. Pelusi, V. Vicennati, U. Pagotto, and R. Pasquali, “Obesity and the polycystic ovary syndrome,” International Journal of Obesity and Related Metabolic Disorders, vol. 26, no. 7, pp. 883–896, 2002. View at Publisher · View at Google Scholar
  60. E. Carmina, “Metabolic syndrome in polycystic ovary syndrome,” Minerva Ginecologica, vol. 58, no. 2, pp. 109–114, 2006. View at Google Scholar · View at Scopus
  61. M.-Y. El-Mir, V. Nogueira, E. Fontaine, N. Avéret, M. Rigoulet, and X. Leverve, “Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I,” The Journal of Biological Chemistry, vol. 275, no. 1, pp. 223–228, 2000. View at Publisher · View at Google Scholar · View at Scopus
  62. M. R. Owen, E. Doran, and A. P. Halestrap, “Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain,” Biochemical Journal, vol. 348, no. 3, pp. 607–614, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. J. D. McGarry and N. F. Brown, “The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis,” European Journal of Biochemistry, vol. 244, no. 1, pp. 1–14, 1997. View at Publisher · View at Google Scholar · View at Scopus
  64. Y. Li, S. Xu, M. M. Mihaylova et al., “AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice,” Cell Metabolism, vol. 13, no. 4, pp. 376–388, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. C. Tebbe, J. Chhina, S. A. Dar et al., “Metformin limits the adipocyte tumor-promoting effect on ovarian cancer,” Oncotarget, vol. 5, no. 13, pp. 4746–4764, 2014. View at Publisher · View at Google Scholar · View at Scopus
  66. Z.-J. Zhang and S. Li, “The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis,” Diabetes, Obesity and Metabolism, vol. 16, no. 8, pp. 707–710, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. J. Kasznicki, A. Sliwinska, and J. Drzewoski, “Metformin in cancer prevention and therapy,” The Annals of Translational Medicine, vol. 2, no. 6, p. 57, 2014. View at Google Scholar
  68. Z.-J. Zhang, Z.-J. Zheng, R. Shi, Q. Su, Q. Jiang, and K. E. Kip, “Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis,” The Journal of Clinical Endocrinology & Metabolism, vol. 97, no. 7, pp. 2347–2353, 2012. View at Publisher · View at Google Scholar · View at Scopus
  69. D. A. Iglesias, M. S. Yates, D. van der Hoeven et al., “Another surprise from metformin: novel mechanism of action via k-Ras influences endometrial cancer response to therapy,” Molecular Cancer Therapeutics, vol. 12, no. 12, pp. 2847–2856, 2013. View at Publisher · View at Google Scholar · View at Scopus
  70. Y. Xie, Y.-L. Wang, L. Yu et al., “Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells,” The Journal of Steroid Biochemistry and Molecular Biology, vol. 126, no. 3–5, pp. 113–120, 2011. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Liao, Q. Zhou, Y. Gu, T. Duan, and Y. Feng, “Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway,” Oncology Reports, vol. 27, no. 6, pp. 1873–1878, 2012. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Algire, O. Moiseeva, X. Deschênes-Simard et al., “Metformin reduces endogenous reactive oxygen species and associated DNA damage,” Cancer Prevention Research, vol. 5, no. 4, pp. 536–543, 2012. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Jiralerspong, S. L. Palla, S. H. Giordano et al., “Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer,” Journal of Clinical Oncology, vol. 27, no. 20, pp. 3297–3302, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. R. J. O. Dowling, M. Zakikhani, I. G. Fantus, M. Pollak, and N. Sonenberg, “Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells,” Cancer Research, vol. 67, no. 22, pp. 10804–10812, 2007. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Zakikhani, R. Dowling, I. G. Fantus, N. Sonenberg, and M. Pollak, “Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells,” Cancer Research, vol. 66, no. 21, pp. 10269–10273, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. B. Liu, Z. Fan, S. M. Edgerton et al., “Metformin induces unique biological and molecular responses in triple negative breast cancer cells,” Cell Cycle, vol. 8, no. 13, pp. 2031–2040, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. H. A. Hirsch, D. Iliopoulos, P. N. Tsichlis, and K. Struhl, “Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission,” Cancer Research, vol. 69, no. 19, pp. 7507–7511, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Del Barco, B. Martin-Castillo, and J. A. Menendez, “The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells,” Breast Cancer Research and Treatment, vol. 126, no. 2, pp. 355–364, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Vazquez-Martin, C. Oliveras-Ferraros, S. Cufí, S. Del Barco, B. Martin-Castilloand, and J. A. Menendez, “Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status,” Cell Cycle, vol. 9, no. 18, pp. 3807–3814, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. G. Stabile, I. Borrielli, A. C. Artenisio et al., “Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome,” The Journal of Pediatric and Adolescent Gynecology, vol. 27, no. 3, pp. 177–182, 2014. View at Publisher · View at Google Scholar · View at Scopus
  81. P. Froment and P. Touraine, “Thiazolidinediones and fertility in polycystic ovary syndrome (PCOS),” PPAR Research, vol. 2006, Article ID 73986, 8 pages, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Google Scholar · View at Scopus
  83. D. J. Kojetin, E. Matta-Camacho, T. S. Hughes et al., “Structural mechanism for signal transduction in RXR nuclear receptor heterodimers,” Nature Communications, vol. 6, article 8013, 2015. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Yki-Järvinen, “Thiazolidinediones,” The New England Journal of Medicine, vol. 351, no. 11, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. J. Girard, “Mechanisms of action of thiazolidinediones,” Diabetes & Metabolism, vol. 27, part 2, pp. 271–278, 2001. View at Google Scholar · View at Scopus
  86. A. Dunaif and A. Thomas, “Current concepts in the polycystic ovary syndrome,” Annual Review of Medicine, vol. 52, pp. 401–419, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. R. Azziz, D. Ehrmann, R. S. Legro et al., “Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial,” Journal of Clinical Endocrinology and Metabolism, vol. 86, no. 4, pp. 1626–1632, 2001. View at Publisher · View at Google Scholar · View at Scopus
  88. W. H. Hu, L. Chen, J. Tong, C. Y. Zhao, S. Mao, and J. Qiao, “Expression of PPARγ mRNA in granulosa cells and its correlation with clinical characteristics of polycystic ovary syndrome,” Beijing Da Xue Xue Bao, vol. 45, no. 6, pp. 859–863, 2013. View at Google Scholar
  89. S. Gasic, M. Nagamani, A. Green, and R. J. Urban, “Troglitazone is a competitive inhibitor of 3β-hydroxysteroid dehydrogenase enzyme in the ovary,” American Journal of Obstetrics and Gynecology, vol. 184, no. 4, pp. 575–579, 2001. View at Publisher · View at Google Scholar · View at Scopus
  90. Y.-M. Mu, T. Yanase, Y. Nishi et al., “Insulin sensitizer, troglitazone, directly inhibits aromatase activity in human ovarian granulosa cells,” Biochemical and Biophysical Research Communications, vol. 271, no. 3, pp. 710–713, 2000. View at Publisher · View at Google Scholar · View at Scopus
  91. N. K. LeBrasseur, M. Kelly, T.-S. Tsao et al., “Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues,” American Journal of Physiology—Endocrinology and Metabolism, vol. 291, no. 1, pp. E175–E181, 2006. View at Publisher · View at Google Scholar · View at Scopus
  92. D. K. Shah, K. M. J. Menon, L. M. Cabrera, A. Vahratian, S. K. Kavoussi, and D. I. Lebovic, “Thiazolidinediones decrease vascular endothelial growth factor (VEGF) production by human luteinized granulosa cells in vitro,” Fertility and Sterility, vol. 93, no. 6, pp. 2042–2047, 2010. View at Publisher · View at Google Scholar · View at Scopus
  93. A. Stuckey, A. Fischer, D. H. Miller et al., “Integrated genomics of ovarian xenograft tumor progression and chemotherapy response,” BMC Cancer, vol. 11, article 308, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. T. M. Livermore, C. Azevedo, B. Kolozsvari, M. S. C. Wilson, and A. Saiardi, “Phosphate, inositol and polyphosphates,” Biochemical Society Transactions, vol. 44, no. 1, pp. 253–259, 2016. View at Publisher · View at Google Scholar · View at Scopus
  95. K. S. Robinson, K. Lai, T. A. Cannon, and P. McGraw, “Inositol transport in Saccharomyces cerevisiae is regulated by transcriptional and degradative endocytic mechanisms during the growth cycle that are distinct from inositol-induced regulation,” Molecular Biology of the Cell, vol. 7, no. 1, pp. 81–89, 1996. View at Publisher · View at Google Scholar · View at Scopus
  96. S. Schneider, “Inositol transport proteins,” FEBS Letters, vol. 589, no. 10, pp. 1049–1058, 2015. View at Publisher · View at Google Scholar · View at Scopus
  97. C. P. Downes and C. H. Macphee, “myo-inositol metabolites as cellular signals,” European Journal of Biochemistry, vol. 193, no. 1, pp. 1–18, 1990. View at Publisher · View at Google Scholar · View at Scopus
  98. K. Strange, R. Morrison, C. W. Heilig, S. DiPietro, and S. R. Gullans, “Upregulation of inositol transport mediates inositol accumulation in hyperosmolar brain cells,” The American Journal of Physiology—Cell Physiology, vol. 260, no. 4, part 1, pp. C784–C790, 1991. View at Google Scholar · View at Scopus
  99. M. L. Croze and C. O. Soulage, “Potential role and therapeutic interests of myo-inositol in metabolic diseases,” Biochimie, vol. 95, no. 10, pp. 1811–1827, 2013. View at Publisher · View at Google Scholar · View at Scopus
  100. A. Bevilacqua and M. Bizzarri, “Physiological role and clinical utility of inositols in polycystic ovary syndrome,” Best Practice & Research Clinical Obstetrics & Gynaecology, 2016. View at Publisher · View at Google Scholar
  101. P. Manna and S. K. Jain, “Phosphatidylinositol-3,4,5-triphosphate and cellular signaling: implications for obesity and diabetes,” Cellular Physiology and Biochemistry, vol. 35, no. 4, pp. 1253–1275, 2015. View at Publisher · View at Google Scholar · View at Scopus
  102. J. M. Stevenson, I. Y. Perera, I. Heilmann, S. Persson, and W. F. Boss, “Inositol signaling and plant growth,” Trends in Plant Science, vol. 5, no. 6, pp. 252–258, 2000. View at Publisher · View at Google Scholar · View at Scopus
  103. R. Valluru and W. Van den Ende, “Myo-inositol and beyond—emerging networks under stress,” Plant Science, vol. 181, no. 4, pp. 387–400, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Balla, “Phosphoinositides: tiny lipids with giant impact on cell regulation,” Physiological Reviews, vol. 93, no. 3, pp. 1019–1137, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. D. Maag, M. J. Maxwell, D. A. Hardesty et al., “Inositol polyphosphate multikinase is a physiologic PI3-kinase that activates Akt/PKB,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 4, pp. 1391–1396, 2011. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Chakraborty, M. A. Koldobskiy, N. T. Bello et al., “Inositol pyrophosphates inhibit akt signaling, thereby regulating insulin sensitivity and weight gain,” Cell, vol. 143, no. 6, pp. 897–910, 2010. View at Publisher · View at Google Scholar · View at Scopus
  107. S. Bang, Y. Chen, R. S. Ahima, and S. F. Kim, “Convergence of IPMK and LKB1-AMPK signaling pathways on metformin action,” Molecular Endocrinology, vol. 28, no. 7, pp. 1186–1193, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. J.-Y. Lee, Y.-R. Kim, J. Park, and S. Kim, “Inositol polyphosphate multikinase signaling in the regulation of metabolism,” Annals of the New York Academy of Sciences, vol. 1271, no. 1, pp. 68–74, 2012. View at Publisher · View at Google Scholar · View at Scopus
  109. S. Kim, S. F. Kim, D. Maag et al., “Amino acid signaling to mTOR mediated by inositol polyphosphate multikinase,” Cell Metabolism, vol. 13, no. 2, pp. 215–221, 2011. View at Publisher · View at Google Scholar · View at Scopus
  110. R. M. Deranieh and M. L. Greenberg, “Cellular consequences of inositol depletion,” Biochemical Society Transactions, vol. 37, no. 5, pp. 1099–1103, 2009. View at Publisher · View at Google Scholar · View at Scopus
  111. J. E. Nestler, D. J. Jakubowicz, P. Reamer, R. D. Gunn, and G. Allan, “Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome,” The New England Journal of Medicine, vol. 340, no. 17, pp. 1314–1320, 1999. View at Publisher · View at Google Scholar · View at Scopus
  112. J.-P. Baillargeon, M. J. Iuorno, T. Apridonidze, and J. E. Nestler, “Uncoupling between insulin and release of a d-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women with polycystic ovary syndrome,” Metabolic Syndrome and Related Disorders, vol. 8, no. 2, pp. 127–136, 2010. View at Publisher · View at Google Scholar · View at Scopus
  113. V. Unfer, G. Carlomagno, G. Dante, and F. Facchinetti, “Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials,” Gynecological Endocrinology, vol. 28, no. 7, pp. 509–515, 2012. View at Publisher · View at Google Scholar · View at Scopus
  114. S. Gerli, E. Papaleo, A. Ferrari, and G. C. Di Renzo, “Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS,” European Review for Medical and Pharmacological Sciences, vol. 11, no. 5, pp. 347–354, 2007. View at Google Scholar · View at Scopus
  115. P. G. Artini, O. M. Di Berardino, F. Papini et al., “Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study,” Gynecological Endocrinology, vol. 29, no. 4, pp. 375–379, 2013. View at Publisher · View at Google Scholar · View at Scopus
  116. F. Facchinetti, G. Dante, and I. Neri, “The ratio of MI to DCI and its impact in the treatment of polycystic ovary syndrome: experimental and literature evidences,” in Frontiers in Gynecological Endocrinology: Volume 3: Ovarian Function and Reproduction—From Needs to Possibilities, ISGE Series, pp. 103–109, Springer, Berlin, Germany, 2016. View at Publisher · View at Google Scholar
  117. M. Nordio and E. Proietti, “The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone,” European Review for Medical and Pharmacological Sciences, vol. 16, no. 5, pp. 575–581, 2012. View at Google Scholar
  118. M. Minozzi, M. Nordio, and R. Pajalich, “The combined therapy myo-inositol plus D-chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients,” European Review for Medical and Pharmacological Sciences, vol. 17, no. 4, pp. 537–540, 2013. View at Google Scholar · View at Scopus
  119. S. Colazingari, M. Treglia, R. Najjar, and A. Bevilacqua, “The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial,” Archives of Gynecology and Obstetrics, vol. 288, no. 6, pp. 1405–1411, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. R. Isabella and E. Raffone, “Does ovary need D-chiro-inositol?” Journal of Ovarian Research, vol. 5, no. 1, article 14, 2012. View at Publisher · View at Google Scholar · View at Scopus
  121. E. Papaleo, V. Unfer, J.-P. Baillargeon et al., “Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction,” Gynecological Endocrinology, vol. 23, no. 12, pp. 700–703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. J.-P. Baillargeon, J. E. Nestler, R. E. Ostlund, T. Apridonidze, and E. Diamanti-Kandarakis, “Greek hyperinsulinemic women, with or without polycystic ovary syndrome, display altered inositols metabolism,” Human Reproduction, vol. 23, no. 6, pp. 1439–1446, 2008. View at Publisher · View at Google Scholar · View at Scopus
  123. K. I. Cheang, J.-P. Baillargeon, P. A. Essah et al., “Insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome,” Metabolism: Clinical and Experimental, vol. 57, no. 10, pp. 1390–1397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  124. M. Falasca, D. Chiozzotto, H. Y. Godage et al., “A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate,” British Journal of Cancer, vol. 102, no. 1, pp. 104–114, 2010. View at Publisher · View at Google Scholar · View at Scopus
  125. W. Han, J. J. Gills, R. M. Memmott, S. Lam, and P. A. Dennis, “The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers,” Cancer Prevention Research, vol. 2, no. 4, pp. 370–376, 2009. View at Publisher · View at Google Scholar · View at Scopus
  126. S. Lam, A. McWilliams, J. LeRiche, C. MacAulay, L. Wattenberg, and E. Szabo, “A phase I study of myo-inositol for lung cancer chemoprevention,” Cancer Epidemiology, Biomarkers & Prevention, vol. 15, no. 8, pp. 1526–1531, 2006. View at Publisher · View at Google Scholar · View at Scopus
  127. I. Vucenik and A. M. Shamsuddin, “Protection against cancer by dietary IP6 and inositol,” Nutrition and Cancer, vol. 55, no. 2, pp. 109–125, 2006. View at Publisher · View at Google Scholar · View at Scopus
  128. Z. Dong, C. Huang, and W.-Y. Ma, “PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer,” Anticancer Research, vol. 19, no. 5, pp. 3743–3747, 1999. View at Google Scholar · View at Scopus
  129. Z. Liu, T.-T. Zhang, J.-J. Zhao et al., “The association between overweight, obesity and ovarian cancer: a meta-analysis,” The Japanese Journal of Clinical Oncology, vol. 45, no. 12, pp. 1107–1115, 2015. View at Publisher · View at Google Scholar · View at Scopus
  130. B. R. Rao and B. J. Slotman, “Endocrine factors in common epithelial ovarian cancer,” Endocrine Reviews, vol. 12, no. 1, pp. 14–26, 1991. View at Publisher · View at Google Scholar · View at Scopus
  131. A. Berchuck, G. J. Olt, L. Everitt, A. P. Soisson, R. C. Bast Jr., and C. M. Boyer, “The role of peptide growth factors in epithelial ovarian cancer,” Obstetrics & Gynecology, vol. 75, no. 2, pp. 255–262, 1990. View at Google Scholar · View at Scopus
  132. A. Gadducci, A. Gargini, E. Palla, A. Fanucchi, and A. R. Genazzani, “Polycystic ovary syndrome and gynecological cancers: is there a link?” Gynecological Endocrinology, vol. 20, no. 4, pp. 200–208, 2005. View at Publisher · View at Google Scholar · View at Scopus
  133. E. G. Silva, C. Tornos, H. A. Fritsche Jr. et al., “The induction of benign epithelial neoplasms of the ovaries of guinea pigs by testosterone stimulation: a potential animal model,” Modern Pathology, vol. 10, no. 9, pp. 879–883, 1997. View at Google Scholar · View at Scopus
  134. A. Evangelou, S. K. Jindal, T. J. Brown, and M. Letarte, “Down-regulation of transforming growth factor β receptors by androgen in ovarian cancer cells,” Cancer Research, vol. 60, no. 4, pp. 929–935, 2000. View at Google Scholar · View at Scopus
  135. M. F. Fathalla, “Incessant ovulation—a factor in ovarian neoplasia?” The Lancet, vol. 298, no. 7716, p. 163, 1971. View at Publisher · View at Google Scholar · View at Scopus
  136. T. Riman, S. Nilsson, and I. R. Persson, “Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies,” Acta Obstetricia et Gynecologica Scandinavica, vol. 83, no. 9, pp. 783–795, 2004. View at Publisher · View at Google Scholar · View at Scopus
  137. D. A. Dumesic and R. A. Lobo, “Cancer risk and PCOS,” Steroids, vol. 78, no. 8, pp. 782–785, 2013. View at Publisher · View at Google Scholar · View at Scopus
  138. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, “Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome,” Fertility and Sterility, vol. 81, no. 1, pp. 19–25, 2004. View at Publisher · View at Google Scholar
  139. J. M. Schildkraut, P. J. Schwingl, E. Bastos, A. Evanoff, and C. Hughes, “Epithelial ovarian cancer risk among women with polycystic ovary syndrome,” Obstetrics & Gynecology, vol. 88, no. 4, part 1, pp. 554–559, 1996. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Balen, “Polycystic ovary syndrome and cancer,” Human Reproduction Update, vol. 7, no. 6, pp. 522–525, 2001. View at Publisher · View at Google Scholar · View at Scopus
  141. C. M. Olsen, A. C. Green, C. M. Nagle et al., “Epithelial ovarian cancer: testing the ‘androgens hypothesis’,” Endocrine-Related Cancer, vol. 15, no. 4, pp. 1061–1068, 2008. View at Publisher · View at Google Scholar · View at Scopus
  142. M. Bodmer, C. Becker, C. Meier, S. S. Jick, and C. R. Meier, “Use of metformin and the risk of ovarian cancer: a case-control analysis,” Gynecologic Oncology, vol. 123, no. 2, pp. 200–204, 2011. View at Publisher · View at Google Scholar · View at Scopus
  143. N. Galazis, O. Olaleye, Z. Haoula, R. Layfield, and W. Atiomo, “Proteomic biomarkers for ovarian cancer risk in women with polycystic ovary syndrome: a systematic review and biomarker database integration,” Fertility and Sterility, vol. 98, no. 6, pp. 1590.e1–1601.e1, 2012. View at Publisher · View at Google Scholar · View at Scopus
  144. J. A. Barry, M. M. Azizia, and P. J. Hardiman, “Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis,” Human Reproduction Update, vol. 20, no. 5, pp. 748–758, 2014. View at Publisher · View at Google Scholar · View at Scopus
  145. C.-C. Shen, A. C. Yang, J.-H. Hung, L.-Y. Hu, and S.-J. Tsai, “A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome,” Oncologist, vol. 20, no. 1, pp. 45–49, 2015. View at Publisher · View at Google Scholar · View at Scopus
  146. M. Gottschau, S. K. Kjaer, A. Jensen, C. Munk, and L. Mellemkjaer, “Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study,” Gynecologic Oncology, vol. 136, no. 1, pp. 99–103, 2015. View at Publisher · View at Google Scholar · View at Scopus
  147. D. J. Joly, A. M. Lilienfeld, E. L. Diamond, and I. D. J. Bross, “An epidemiologic study of the relationship of reproductive experience to cancer of the ovary,” The American Journal of Epidemiology, vol. 99, no. 3, pp. 190–209, 1974. View at Google Scholar · View at Scopus
  148. J.-Y. Lee, I. Jeon, J. W. Kim, Y.-S. Song, J.-M. Yoon, and S. M. Park, “Diabetes mellitus and ovarian cancer risk: a systematic review and meta-analysis of observational studies,” International Journal of Gynecological Cancer, vol. 23, no. 3, pp. 402–412, 2013. View at Publisher · View at Google Scholar · View at Scopus
  149. C. Rodriguez, E. E. Calle, D. Fakhrabadi-Shokoohi, E. J. Jacobs, and M. J. Thun, “Body mass index, height, and the risk of ovarian cancer mortality in a prospective cohort of postmenopausal women,” Cancer Epidemiology, Biomarkers & Prevention, vol. 11, no. 9, pp. 822–828, 2002. View at Google Scholar · View at Scopus
  150. G. Libby, L. A. Donnelly, P. T. Donnan, D. R. Alessi, A. D. Morris, and J. M. M. Evans, “New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes,” Diabetes Care, vol. 32, no. 9, pp. 1620–1625, 2009. View at Publisher · View at Google Scholar · View at Scopus
  151. J. M. M. Evans, L. A. Donnelly, A. M. Emslie-Smith, D. R. Alessi, and A. D. Morris, “Metformin and reduced risk of cancer in diabetic patients,” British Medical Journal, vol. 330, no. 7503, pp. 1304–1305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  152. L. A. Stadtmauer, B. C. Wong, and S. Oehninger, “Should patients with polycystic ovary syndrome be treated with metformin? Benefits of insulin sensitizing drugs in polycystic ovary syndrome—beyond ovulation induction,” Human Reproduction, vol. 17, no. 12, pp. 3016–3026, 2002. View at Publisher · View at Google Scholar · View at Scopus
  153. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2015/.
  154. T. Fornander, B. Cedermark, A. Mattsson et al., “Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers,” The Lancet, vol. 333, no. 8630, pp. 117–120, 1989. View at Publisher · View at Google Scholar · View at Scopus
  155. Y. Tingthanatikul, W. Choktanasiri, M. Rochanawutanon, and S. Weerakeit, “Prevalence and clinical predictors of endometrial hyperplasiain anovulatory women presenting with amenorrhea,” Gynecological Endocrinology, vol. 22, no. 2, pp. 101–105, 2006. View at Publisher · View at Google Scholar · View at Scopus
  156. N. S. L. Holm, D. Glintborg, M. S. Andersen, D. Schledermann, and P. Ravn, “The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism,” Acta Obstetricia et Gynecologica Scandinavica, vol. 91, no. 10, pp. 1173–1176, 2012. View at Publisher · View at Google Scholar · View at Scopus
  157. M. N. Shafiee, G. Khan, R. Ariffin et al., “Preventing endometrial cancer risk in polycystic ovarian syndrome (PCOS) women: could metformin help?” Gynecologic Oncology, vol. 132, no. 1, pp. 248–253, 2014. View at Publisher · View at Google Scholar · View at Scopus
  158. P. Hardiman, O. S. Pillay, and W. Atiomo, “Polycystic ovary syndrome and endometrial carcinoma,” The Lancet, vol. 361, no. 9371, pp. 1810–1812, 2003. View at Publisher · View at Google Scholar · View at Scopus
  159. Z. Haoula, M. Salman, and W. Atiomo, “Evaluating the association between endometrial cancer and polycystic ovary syndrome,” Human Reproduction, vol. 27, no. 5, pp. 1327–1331, 2012. View at Publisher · View at Google Scholar · View at Scopus
  160. G. Zhang, X. Li, L. Zhang et al., “The expression and role of hybrid insulin/insulin-like growth factor receptor type 1 in endometrial carcinoma cells,” Cancer Genetics and Cytogenetics, vol. 200, no. 2, pp. 140–148, 2010. View at Publisher · View at Google Scholar · View at Scopus
  161. E. E. Sheets, J. C. M. Tsibris, N. I. Cook, S. D. Virgin, R. M. DeMay, and W. N. Spellacy, “In vitro binding of insulin and epidermal growth factor to human endometrium and endocervix,” American Journal of Obstetrics and Gynecology, vol. 153, no. 1, pp. 60–65, 1985. View at Publisher · View at Google Scholar · View at Scopus
  162. A. Zucchetto, D. Serraino, J. Polesel et al., “Hormone-related factors and gynecological conditions in relation to endometrial cancer risk,” European Journal of Cancer Prevention, vol. 18, no. 4, pp. 316–321, 2009. View at Publisher · View at Google Scholar · View at Scopus
  163. S. Wild, T. Pierpoint, H. Jacobs, and P. McKeigue, “Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study,” Human Fertility, vol. 3, no. 2, pp. 101–105, 2000. View at Publisher · View at Google Scholar · View at Scopus
  164. E. J. Fearnley, L. Marquart, A. B. Spurdle, P. Weinstein, and P. M. Webb, “Polycystic ovary syndrome increases the risk of endometrial cancer in women aged less than 50 years: an Australian case-control study,” Cancer Causes & Control, vol. 21, no. 12, pp. 2303–2308, 2010. View at Publisher · View at Google Scholar · View at Scopus
  165. K. Niwa, A. Imai, M. Hashimoto et al., “A case-control study of uterine endometrial cancer of pre- and post-menopausal women,” Oncology Reports, vol. 7, no. 1, pp. 89–93, 2000. View at Google Scholar · View at Scopus
  166. B. G. Chittenden, G. Fullerton, A. Maheshwari, and S. Bhattacharya, “Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review,” Reproductive BioMedicine Online, vol. 19, no. 3, pp. 398–405, 2009. View at Publisher · View at Google Scholar · View at Scopus
  167. L. G. Escobedo, N. C. Lee, H. B. Peterson, and P. A. Wingo, “Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women,” Obstetrics & Gynecology, vol. 77, no. 1, pp. 124–128, 1991. View at Google Scholar · View at Scopus
  168. B. C. J. M. Fauser, B. C. Tarlatzis, R. W. Rebar et al., “Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group,” Fertility and Sterility, vol. 97, no. 1, pp. 28–e25, 2012. View at Publisher · View at Google Scholar · View at Scopus
  169. R. J. Shaw, K. A. Lamia, D. Vasquez et al., “The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin,” Science, vol. 310, no. 5754, pp. 1642–1646, 2005. View at Publisher · View at Google Scholar
  170. S. Dronavalli and D. A. Ehrmann, “Pharmacologic therapy of polycystic ovary syndrome,” Clinical Obstetrics and Gynecology, vol. 50, no. 1, pp. 244–254, 2007. View at Publisher · View at Google Scholar · View at Scopus
  171. T. Sinai, T. Tang, and E. Yasmin, “Role of metformin in women's health: review of its current place in clinical practice and emerging indications for future,” Obstetrical & Gynecological Survey, vol. 71, no. 5, pp. 307–317, 2016. View at Google Scholar
  172. L. Aghajanova, M. C. Velarde, and L. C. Giudice, “Altered gene expression profiling in endometrium: evidence for progesterone resistance,” Seminars in Reproductive Medicine, vol. 28, no. 1, pp. 51–58, 2010. View at Publisher · View at Google Scholar · View at Scopus
  173. X. Li, Y. Feng, J.-F. Lin, H. Billig, and R. Shao, “Endometrial progesterone resistance and PCOS,” Journal of biomedical science, vol. 21, article 2, 2014. View at Publisher · View at Google Scholar · View at Scopus
  174. R. Sarfstein, Y. Friedman, Z. Attias-Geva, A. Fishman, I. Bruchim, and H. Werner, “Metformin downregulates the insulin/IGF-I signaling pathway and inhibits different uterine serous carcinoma (USC) cells proliferation and migration in p53-dependent or -independent manners,” PLoS ONE, vol. 8, no. 4, Article ID e61537, 2013. View at Publisher · View at Google Scholar · View at Scopus
  175. N. S. Nevadunsky, A. Van Arsdale, H. D. Strickler et al., “Metformin use and endometrial cancer survival,” Gynecologic Oncology, vol. 132, no. 1, pp. 236–240, 2014. View at Publisher · View at Google Scholar · View at Scopus
  176. E. M. Ko, P. Walter, A. Jackson et al., “Metformin is associated with improved survival in endometrial cancer,” Gynecologic Oncology, vol. 132, no. 2, pp. 438–442, 2014. View at Publisher · View at Google Scholar · View at Scopus
  177. C. Becker, S. S. Jick, C. R. Meier, and M. Bodmer, “Metformin and the risk of endometrial cancer: a case-control analysis,” Gynecologic Oncology, vol. 129, no. 3, pp. 565–569, 2013. View at Publisher · View at Google Scholar · View at Scopus
  178. M. Costello, B. Shrestha, J. Eden, P. Sjoblom, and N. Johnson, “Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome,” The Cochrane Database of Systematic Reviews, vol. 1, Article ID CD005552, 2007. View at Google Scholar
  179. “Metformin for the Treatment of Endometrial Hyperplasia,” ClinicalTrials.gov Identifier NCT01685762, 2016, https://clinicaltrials.gov/ct2/home.
  180. UNC Lineberger Comprehensive Cancer Center, “Metformin with the levonorgestrel-releasing intrauterine device for the treatment of complex atypical hyperplasia (CAH) and endometrial cancer (EC) in non-surgical patients,” clinical trial.gov identifier: NCT 02035787, 2016.